2638
T. Guntreddi et al.
LETTER
Table 2 One-Pot Three-Component Coupling of 2-Amino Pyridine, Aldehyde, and Alkynea (continued)
Entry Aldehyde 2
Alkyne 3
Product 4
Time (h) Yield (%)b
15
2o
3b
4o
20
82
Hex
N
Ph
O
N
Hex
a Using 1 (1 mmol), 2 (1 mmol), 3 (1.2 mmol), nano-Fe3O4 (0.1 mmol) and KHSO4·SiO2 (150 mg) at 110 °C in anhyd toluene.
b Isolated yield after column chromatography.
c Using KHSO4·SiO2 (175 mg).
(c) Singh, N.; Singh, S. K.; Khanna, R. S.; Singh, K. N.
Tetrahedron Lett. 2011, 52, 2419. (d) Kumari, K.;
Raghuvanshi, D. S.; Jouikov, V.; Singh, K. N. Tetrahedron
Lett. 2012, 53, 1130. (e) Raghuvanshi, D. S.; Singh, K. N.
Tetrahedron Lett. 2011, 52, 5702. (f) Raghuvanshi, D. S.;
Singh, K. N. Synlett 2011, 373.
Acknowledgement
We thank the Council of Scientific and Industrial Research (CSIR),
New Delhi for financial assistance.
References
(8) General Experimental Procedure: To an oven-dried 25
mL round-bottom flask containing a magnetic stir bar was
added 2-aminopyridine (1 mmol, 94.1 mg), aldehyde (1
mmol), KHSO4·SiO2 (150 mg, 0.032 mmol with respect to
KHSO4), and anhyd toluene (2 mL). The mixture was stirred
for 15 min and to it was then added alkyne (1.2 mmol) and
nano-Fe3O4 [<50 nm particle size, ≥98% trace metals basis
(Aldrich)] (0.1 mmol, 23.2 mg). The total reaction mixture
was refluxed at 110 °C for the appropriate time. After
completion of the reaction (monitored by TLC), EtOAc was
added (10 mL), the magnetic Fe3O4 nanoparticles were
collected on the magnetic stir bar, and the mixture was
filtered through a porous plug. The filtrate was concentrated
under reduced pressure and the crude product thus obtained,
was purified by silica gel column chromatography (EtOAc–
hexane, 1:9). The pure products were characterized based
upon their physical and spectroscopic properties.
(1) Zhu, J.; Bienaymé, H. Multicomponent Reactions; Wiley-
VCH: Weinheim, 2005.
(2) Dömling, A.; Wang, W.; Wang, K. Chem. Rev. 2012, 112,
3083.
(3) (a) Horton, D. A.; Bourne, G. T.; Smythe, M. L. Chem. Rev.
2003, 103, 893. (b) Constantino, L.; Barlocco, D. Curr. Med.
Chem. 2006, 13, 65.
(4) (a) Oishi, H.; Takano, K.-i.; Tomita, K.; Takebe, M.; Yokoo,
H.; Yamazaki, M.; Hattori, Y. Am. J. Physiol. Lung Cell
Mol. Physiol. 2012, 303, L130. (b) Yamane, I.; Hagino, H.;
Okano, T.; Enokida, M.; Yamasaki, D.; Teshima, R.
Arthritis Rheum. 2003, 48, 1732. (c) Kim, O.; Jeong, Y.;
Lee, H.; Hong, S.-S.; Hong, S. J. Med. Chem. 2011, 54,
2455. (d) Trabanco, A. A.; Tresadern, G.; Macdonald, G. J.;
Vega, J. A.; de Lucas, A. I.; Matesanz, E.; García, A.;
Linares, M. L.; de Diego, S. A. A.; Alonso, J. M.; Oehlrich,
D.; Ahnaou, A.; Drinkenburg, W.; Mackie, C.; Andres, J. I.;
Lavreysen, H.; Cid, J. M. J. Med. Chem. 2012, 55, 2688.
(e) Kamal, A.; Surendranadha Reddy, J.; Janaki Ramaiah,
M.; Dastagiri, D.; Vijaya Bharathi, E.; Victor Prem Sagar,
M.; Pushpavalli, S. N. C. V. L.; Ray, P.; Pal-Bhadra, M.
Med. Chem. Commun. 2010, 1, 355. (f) Langer, S. Z.;
Arbilla, S.; Benavides, J.; Scatton, B. Adv. Biochem.
Psychopharmacol. 1990, 46, 61. (g) Lhassani, M.;
Chavignon, O.; Chezal, J.-M.; Teulade, J.-C.; Chapat, J.-P.;
Snoeck, R.; Andrei, G.; Balzarini, J.; De Clercq, E.;
Gueiffier, A. Eur. J. Med. Chem. 1999, 34, 271.
(5) (a) Chernyak, N.; Gevorgyan, V. Angew. Chem. Int. Ed.
2010, 49, 2743. (b) Reddy, B. V. S.; Reddy, P. S.; Reddy, Y.
J.; Yadav, J. S. Tetrahedron Lett. 2011, 52, 5789. (c) Liu, P.;
Fang, L.-s.; Lei, X.; Lin, G.-q. Tetrahedron Lett. 2010, 51,
4605. (d) Mishra, S.; Ghosh, R. Synthesis 2011, 3463.
(6) (a) Polshettiwar, V.; Luque, R.; Fihri, A.; Zhu, H.; Bouhrara,
M.; Basset, J. M. Chem. Rev. 2011, 111, 3036. (b) Shylesh,
S.; Schunemann, V.; Thiel, W. R. Angew. Chem. Int. Ed.
2010, 49, 3428. (c) Firouzabadi, H.; Iranpoor, N.;
Gholinejad, M.; Hoseini, J. Adv. Synth. Catal. 2011, 353,
125. (d) Zhang, Z.-H.; Lu, H.-Y.; Yang, S.-H.; Gao, J.-W. J.
Comb. Chem. 2010, 12, 643. (e) Martínez, R.; Ramón, D. J.;
Yus, M. Adv. Synth. Catal. 2008, 350, 1235.
Spectroscopic Data of the Representative Compounds:
3-Benzyl-2-(3-chlorophenyl)imidazo[1,2-a]pyridine (4c):
White solid; mp = 141–142 °C. 1H NMR (300 MHz,
CDCl3): δ = 7.77 (s, 1 H), 7.65–7.53 (m, 3 H), 7.27–7.22 (m,
4 H), 7.21–7.10 (m, 2 H), 7.07 (d, J = 6.6 Hz, 2 H), 6.68–
6.64 (m, 1 H), 4.42 (s, 2 H) ppm. 13C NMR (75 MHz,
CDCl3): δ = 143.7, 142.2, 136.1, 135.9, 134.4, 132.0, 129.9,
129.6, 129.3, 128.1, 127.9, 127.7, 126.9, 126.3, 124.8,
123.3, 118.0, 117.7, 112.4, 29.9 ppm.
3-Benzyl-2-(4-tolyl)imidazo[1,2-a]pyridine (4i): Pale
yellow solid; mp = 160–161 °C. 1H NMR (300 MHz,
CDCl3): δ = 7.69 (t, J = 8.1 Hz, 4 H), 7.26 (br s, 5 H), 7.16–
7.13 (m, 3 H), 6.70 (br s, 1 H), 4.49 (s, 2 H), 2.39 (s, 3 H)
ppm. 13C NMR (75 MHz, CDCl3): δ = 144.6, 144.0, 137.7,
136.6, 131.9, 129.0, 128.9, 128.2, 127.6, 126.7, 124.1,
123.1, 117.5, 117.3, 112.0, 30.1, 21.1 ppm.
(9) For the preparation of KHSO4·SiO2, see: Goswami, N.; Das,
R. N.; Borthakur, N. Ind. J. Chem., Sect. B: Org. Chem. Incl.
Med. Chem. 2007, 46, 1893.
(10) Reusability of magnetic nano-Fe3O4: After completion of the
reaction EtOAc was added and the Fe3O4-nanoparticles were
recovered by the application of an external magnet. The
recovered nanoparticles were thoroughly washed with Et2O,
dried at 130 °C for 1 h and then reused for a new catalytic
cycle.
(7) (a) Allam, B. K.; Singh, K. N. Tetrahedron Lett. 2011, 52,
5851. (b) Allam, B. K.; Singh, K. N. Synthesis 2011, 1125.
Synlett 2012, 23, 2635–2638
© Georg Thieme Verlag Stuttgart · New York